Title: QUALITY USE OF CARDIOVASCULAR MEDICATION
1QUALITY USE OF CARDIOVASCULAR MEDICATION
2Prescription Drugs and Drug Trials
- Drug development
- - basic science research in a laboratory
- - chemical patented (20 years)
- - laboratory testing
- - Phase 1 trials tested for safety and
efficacy in animals - - Phase 2 trials tested for safety in normal
humans - - Phase 3 trials show effective (better than
placebo or current standard treatment) and safe
in many thousands of patients around the world
(double blind
3- Drug launched (5 years patent remaining)
- - post marketing surveillance
- 100 million
- Register with FDA / MCC (years)
4Alternative Drugs
- Vitamins
- Minerals
- Cholesterol vaporises
- Tissue salts
- NO RESEARCH
- NO EVIDENCE OF EFFICACY
- NO PRODUCTION CONTROL
- NO REGISTRATION PROCESS
- Trials done consistently show NO benefit eg.
Folate, anti-oxidant vitamins
5Conspiracy Theory
- Doctors and Universities bribed / kick backs
from pharmaceutical companies? - Lack of patient trust?
- Only want natural treatment ( death?)
6Commonly Used Drugs
- Statins -reduce cholesterol
- - Zocor, Simvastatin, Lipitor, Aspavor, Crestor,
Prava, Lescol - primary prevention (at risk but currently
asymptomatic) - benefit in high risk persons
- or
- - secondary prevention (known with coronary
artery disease) - 30 reduction in future heart attack and stroke
- Aspirin - reduces blood stickiness
- primary (little benefit) or secondary
prevention (25 ) - ACE-I / ARB lower BP, improve heart failure
- - Prexum, Coversyl, Lisinopril, Zetomax,
Pharmapres, Enalapril, Cozaar, Zartan, Diovan
7Commonly Used Drugs
- Beta Blockers reduce heart rate (angina) and
BP, heart failure - - Concor, Bilocor, Bisocor, Carloc, Dilatrend
- Calcium Channel blockers reduce heart rate and
BP - - Verahexal, Calcicard, Ravamil, Amloc, Norvasc,
Zildem
8New Comers
- Coralin reduces heart rate without decreasing
BP and no BB side effects (lethargy, impotence) - - angina and heart failure
- Dabigatran thins blood like Warfarin but no INR
(blood) testing needed - - atrial fibrillation
9Guideline recommendations for BP goals
- lt140/90mmHg for essential hypertension
- lt130/80mmHg for hypertensive patients with
diabetes - Most patients with hypertension will require two
or more antihypertensive agents to achieve BP goal
ESH/ESC European Society of Hypertension/Europea
n Society of Cardiology JNC 7 Joint National
Committee on Prevention, Detection, Evaluation,
and Treatment of High Blood Pressure, seventh
report
Guidelines Committee. J Hypertens 2003 21
1011-53. Chobanian AV, et al. JAMA 2003 289
2560-72.
10Combination therapy needed to achieve target SBP
goals
INVEST data on file. ALLHAT Collaborative
Research Group. JAMA 2002 288 2981-97. Brenner
BM, et al. N Engl J Med 2001 345 861-9. Lewis
EJ, et al. N Engl J Med 2001 345
851-60. Adapted from Bakris GL, et al. Am J
Kidney Dis 2000 36 646-61.
11Hypertension a risk factor forcardiovascular
morbidity and mortality
Risk ratio 2.0 2.2 3.8 2.5 2.0 3.7 4.0 3.0 Excess
risk 22.7 11.6 9.1 3.8 4.9 5.3 10.4 4.2
Kannel WB. JAMA 1996 275 1571-6.
12MRFIT association of systolic BP and diabetes
with cardiovascular risk
Stamler J, et al. Diabetes Care 1993 16 434-44.
13Early morning BP surge coincides with peak
incidences of stroke and myocardial infarction
Time of day
McInnes G. J Am Soc Hypertens 20082S1622.
14(No Transcript)